News

People with hereditary transthyretin amyloidosis (hATTR) should be checked for polyneuropathy (damage to multiple nerves) in addition to cardiomyopathy (heart damage), a study in the…

Treatment with Vyndamax (tafamidis) improves certain features of the heart’s structure and function in adults with transthyretin amyloid cardiomyopathy (ATTR-CM), according to an…

Onpattro (patisiran) slows neuropathy (nerve damage) progression in people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) who respond poorly to tafamidis meglumine, a…

Attruby (acoramidis) may be better than Vyndamax (tafamidis) at preserving heart health among people with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a…

A newly developed questionnaire may help flag early signs of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in people carrying mutations in the TTR gene that…

Women with transthyretin amyloid cardiomyopathy (ATTR-CM) showed different clinical characteristics than men with the condition in pooled data from two previous studies of patients…

Early-career researchers studying transthyretin amyloidosis (ATTR), a group of conditions that includes hereditary ATTR with polyneuropathy (hATTR-PN) and ATTR cardiomyopathy (ATTR-CM), are being…

The approved therapy Attruby (acoramidis) may not only slow the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), but it may also help reverse heart…

In people with transthyretin amyloid cardiomyopathy (ATTR-CM), treatment with the approved therapy Amvuttra (vutrisiran) may help reduce the risk of death and serious heart…

A family history of nerve disease, carpal tunnel syndrome in both hands, and balance problems are the “clinical ‘red flags'” most strongly linked to a…